Abstract
We identified nine naturally-occurring human single nucleotide polymorphisms (SNPs) in the α1a-adrenoceptor (α1aAR) coding region, seven of which result in amino acid change. Utilizing rat-1 fibroblasts stably expressing wild type α1aAR or each SNP at both high and low levels, we investigated the effect of these SNPs on receptor function. Compared with wild type, two SNPs (R166K, V311I) cause a decrease in binding affinity for agonists norepinephrine, epinephrine, and phenylephrine, and also shift the dose–response curve for norepinephrine stimulation of inositol phosphate (IP) production to the right (reduced potency) without altering maximal IP activity. In addition, SNP V311I and I200S display altered antagonist binding. Interestingly, a receptor with SNP G247R (located in the third intracellular loop) displays increased maximal receptor IP activity and stimulates cell growth. The increased receptor signaling for α1aAR G247R is not mediated by altered ligand binding or a deficiency in agonist-mediated desensitization, but appears to be related to enhanced receptor–G protein coupling. In conclusion, four naturally-occurring human α1aAR SNPs induce altered receptor pharmacology and/or biological activity. This finding has potentially important implications in many areas of medicine and can be used to guide α1aAR SNP choice for future clinical studies.
Similar content being viewed by others
References
Autelitano DJ, Woodcock EA (1998) Selective activation of alpha1A-adrenergic receptors in neonatal cardiac myocytes is sufficient to cause hypertrophy and differential regulation of alpha1-adrenergic receptor subtype mRNAs. J Mol Cell Cardiol 30:1515–1523
Aynacioglu AS, Cascorbi I, Gungor K, Ozkur M, Bekir N, Roots I, Brockmoller J (1999) Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu and Thr164Ile polymorphisms in the beta2-adrenergic receptor among Turks. Br J Clin Pharmacol 48:761–764
Bolonna AA, Arranz MJ, Munro J, Osborne S, Petouni M, Martinez M, Kerwin RW (2000) No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 280:65–68
Brodde OE, Buscher R, Tellkamp R, Radke J, Dhein S, Insel PA (2001) Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation 103:1048–1050
Chen S, Xu M, Lin F, Lee D, Riek P, Graham RM (1999) Phe310 in transmembrane VI of the alpha1B-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding. J Biol Chem 274:16320–16330
Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH (2004) Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305:869–872
Cornwell TL, Arnold E, Boerth NJ, Lincoln TM (1994) Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 267:C1405–C1413
Erami C, Zhang H, Ho JG, French DM, Faber JE (2002) Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo. Am J Physiol Heart Circ Physiol 283:H1577–H1587
Gordon D, Abajian C, Green P (1998) Consed: a graphical tool for sequence finishing. Genome Res 8:195–202
Graham RM, Perez DM, Hwa J, Piascik MT (1996) alpha 1-adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ Res 78:737–749
Greasley PJ, Fanelli F, Scheer A, Abuin L, Nenniger-Tosato M, DeBenedetti PG, Cotecchia S (2001) Mutational and computational analysis of the alpha(1b)-adrenergic receptor. Involvement of basic and hydrophobic residues in receptor activation and G protein coupling. J Biol Chem 276:46485–46494
Green SA, Cole G, Jacinto M, Innis M, Liggett SB (1993) A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268:23116–23121
Green SA, Rathz DA, Schuster AJ, Liggett SB (2001) The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 421:141–147
Hamaguchi N, True TA, Saussy DL Jr, Jeffs PW (1996) Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 35:14312–14317
Hawrylyshyn KA, Michelotti GA, Coge F, Guenin S-P, Schwinn DA (2004) Update on human alpha1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol Sci 25:449–455
Hoehe MR, Berrettini WH, Schwinn DA, Hsieh WT (1992) A two-allele PstI RFLP for the alpha-1C adrenergic receptor gene (ADRA1C). Hum Mol Genet 1:349
Hwa J, Perez DM (1996) The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation. J Biol Chem 271:6322–6327
Hwa J, Graham RM, Perez DM (1995) Identification of critical determinants of alpha 1-adrenergic receptor subtype selective agonist binding. J Biol Chem 270:23189–23195
Kirstein SL, Insel PA (2004) Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev 56:31–52
Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA (1998) The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102:1534–1539
Mason DA, Moore JD, Green SA, Liggett SB (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 274:12670–12674
Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB (2003) Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9:1300–1305
Michelotti GA, Price DT, Schwinn DA (2000) Alpha 1-adrenergic receptor regulation: basic science and clinical implications. Pharmacol Ther 88:281–309
Mimura Y, Kobayashi S, Notoya K, Okabe M, Kimura I, Horikoshi I, Kimura M (1995) Activation by alpha 1-adrenergic agonists of the progression phase in the proliferation of primary cultures of smooth muscle cells in mouse and rat aorta. Biol Pharm Bull 18:1373–1376
Nickerson DA, Tobe VO, Taylor SL (1997) PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 25:2745–2751
Piascik MT, Perez DM (2001) Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther 298:403–410
Porter JE, Perez DM (1999) Characteristics for a salt-bridge switch mutation of the alpha(1b) adrenergic receptor. Altered pharmacology and rescue of constitutive activity. J Biol Chem 274:34535–34538
Porter JE, Hwa J, Perez DM (1996) Activation of the alpha1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J Biol Chem 271:28318–28323
Porton B, Ferreira A, DeLisi LE, Kao HT (2004) A rare polymorphism affects a mitogen-activated protein kinase site in synapsin III: possible relationship to schizophrenia. Biol Psychiatry 55:118–125
Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, Schwinn DA (1994) Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. Mol Pharmacol 45:171–175
Price RR, Morris DP, Biswas G, Smith MP, Schwinn DA (2002) Acute agonist-mediated desensitization of the human alpha 1a-adrenergic receptor is primarily independent of carboxyl terminus regulation: implications for regulation of alpha 1aAR splice variants. J Biol Chem 277:9570–9579
Roehrborn CG, Schwinn DA (2004) Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 171:1029–1035
Rokosh DG, Simpson PC (2002) Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 99:9474–9479
Rokosh DG, Stewart AF, Chang KC, Bailey BA, Karliner JS, Camacho SA, Long CS, Simpson PC (1996) Alpha1-adrenergic receptor subtype mRNAs are differentially regulated by alpha1-adrenergic and other hypertrophic stimuli in cardiac myocytes in culture and in vivo. Repression of alpha1B and alpha1D but induction of alpha1C. J Biol Chem 271:5839–5843
Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D’Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA (1999) Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 100:2336–2343
Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ et al (1995) Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther 272:134–142
Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, Tsujimoto G (1996) Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol 118:1403–1408
Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB (2002) Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135–1142
Snapir A, Heinonen P, Tuomainen TP, Alhopuro P, Karvonen MK, Lakka TA, Nyyssonen K, Salonen R, Kauhanen J, Valkonen VP, Pesonen U, Koulu M, Scheinin M, Salonen JT (2001) An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol 37:1516–1522
Sofowora GG, Dishy V, Landau R, Xie HG, Prasad HC, Byrne DW, Smiley RM, Kim RB, Wood AJ, Stein CM (2004) Alpha 1A-adrenergic receptor polymorphism and vascular response. Clin Pharmacol Ther 75:539–545
Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, Dixon RA (1987) Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci USA 84:4384–4388
Svetkey LP, Timmons PZ, Emovon O, Anderson NB, Preis L, Chen YT (1996) Association of hypertension with beta2- and alpha2c10-adrenergic receptor genotype. Hypertension 27:1210–1215
Wang XL, Liu SX, McCredie RM, Wilcken DE (1996) Polymorphisms at the 5′-end of the apolipoprotein AI gene and severity of coronary artery disease. J Clin Invest 98:372–377
Waugh DJ, Zhao MM, Zuscik MJ, Perez DM (2000) Novel aromatic residues in transmembrane domains IV and V involved in agonist binding at alpha(1a)-adrenergic receptors. J Biol Chem 275:11698–11705
Waugh DJ, Gaivin RJ, Zuscik MJ, Gonzalez-Cabrera P, Ross SA, Yun J, Perez DM (2001) Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like antagonists. J Biol Chem 276:25366–25371
Xiao L, Pimental DR, Amin JK, Singh K, Sawyer DB, Colucci WS (2001) MEK1/2–ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33:779–787
Xie HG, Kim RB, Stein CM, Gainer JV, Brown NJ, Wood AJ (1999) Alpha1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. Pharmacogenetics 9:651–656
Zhao MM, Hwa J, Perez DM (1996) Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding. Mol Pharmacol 50:1118–1126
Acknowledgements
This study was supported in part by NIH grants #AG17556 (DAS), #HL67974 (JIR), #HL55005 (TAB), NCRR#RR43 (TAB), NCRR#RR30 (DAS) and a NHGRI Visiting Investigator Program (VIP) Award (DAS), NHGRI (EDG), and the Cedar-Sinai, Board of Governors’ Chair in Medical Genetics (JIR). Dr. Schwinn is a senior fellow in the Center for the Study of Aging and Human Development at Duke University. We would like to take this opportunity to thank Jackie Idol for technical assistance in defining human α1aAR polymorphisms, Gregory A. Michelotti, PhD, for helpful conversations, and Zarrin T. Brooks for assistance in manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lei, B., Morris, D.P., Smith, M.P. et al. Novel human α1a-adrenoceptor single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn-Schmiedeberg's Arch Pharmacol 371, 229–239 (2005). https://doi.org/10.1007/s00210-005-1019-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-005-1019-9